Interleukin-6 as a Predictor of the Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Epidemiological Studies

References

• Biswas P, Delfanti F, Bernasconi S, et al. (1998). Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood, 91, 258–265.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Luc G, Ducimetiere P, et al. (2003). Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation, 108, 2453–2459. doi:10.1161/01.cir.0000099509.76044.a2
   PubMed Web of Science ®Google Scholar
• Bologa RM, Levine DM, Parker TS, et al. (1998). Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis, 32, 107–114. doi:10.1053/ajkd.1998.v32.pm9669431
   PubMed Web of Science ®Google Scholar
• Cesari M, Penninx BW, Newman AB, et al. (2003). Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation, 108, 2317–2322. doi:10.1161/01.cir.0000097109.90783.fc
   PubMed Web of Science ®Google Scholar
• Danesh J, Kaptoge S, Mann AG, et al. (2008). Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med, 5, e78. doi:10.1371/journal.pmed.0050078
   PubMed Web of Science ®Google Scholar
• Ettinger Jr. WH, Sun WH, Binkley N, et al. (1995). Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys. J Gerontol A Biol Sci Med Sci, 50, M137–40. doi:10.1093/gerona/50A.3.M137
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Broch M, Vendrell J, et al. (2000). Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab, 85, 1334–1339. doi:10.1210/jcem.85.3.6555
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Vayreda M, Richart C, et al. (2001). Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab, 86, 1154–1159. doi:10.1210/jcem.86.3.7305
   PubMed Web of Science ®Google Scholar
• Fisman EZ, Benderly M, Esper RJ, et al. (2006). Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol, 98, 14–18. doi:10.1016/j.amjcard.2006.01.045
   PubMed Web of Science ®Google Scholar
• Fraser A, May M, Lowe G, et al. (2009). Interleukin-6 and incident coronary heart disease: results from the British women’s heart and health study. Atherosclerosis, 202, 567–572. doi:10.1016/j.atherosclerosis.2008.04.048
   PubMed Web of Science ®Google Scholar
• Gotsman I, Stabholz A, Planer D, et al. (2008). Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J, 10, 494–498.
   PubMed Web of Science ®Google Scholar
• Haddy N, Sass C, Droesch S, et al. (2003). IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis, 170, 277–283. doi:10.1016/S0021-9150(03)00287-9
   PubMed Web of Science ®Google Scholar
• Hansson GK. (2005). Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 352, 429–430. doi:10.1056/NEJMra043430
   Web of Science ®Google Scholar
• Hartford M, Wiklund O, Mattsson Hulten L, et al. (2007). C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med, 262, 526–536. doi:10.1111/j.1365-2796.2007.01862.x
   PubMed Web of Science ®Google Scholar
• Hashizume M, Yoshida H, Koike N, et al. (2010). Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis, 69, 741–746. doi:10.1136/ard.2008.104844
   PubMed Web of Science ®Google Scholar
• Hedman A, Larsson PT, Alam M, et al. (2007). CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? Int J Cardiol, 120, 108–114. doi:10.1016/j.ijcard.2006.09.004
   PubMed Web of Science ®Google Scholar
• Hill GE, Pohorecki R, Whitten CW. (1998). Plasma lipid concentrations correlate inversely with CPB-induced interleukin-6 release. Can J Anaesth, 45, 509–514. doi:10.1007/bf03012699
   PubMed Web of Science ®Google Scholar
• Jefferis BJ, Papacosta O, Owen CG, et al. (2011). Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis, 217, 227–233. doi:10.1016/j.atherosclerosis.2011.03.015
   PubMed Web of Science ®Google Scholar
• Jefferis BJ, Whincup PH, Welsh P, et al. (2013). Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79 years: a nested case-control study. Cytokine, 61, 513–520. doi:10.1016/j.cyto.2012.10.010
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Baumert J, et al. (2006). Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol, 26, 2745–2751. doi:10.1161/01.atv.0000248096.62495.73
   PubMed Web of Science ®Google Scholar
• Lee KW, Lip GY, Tayebjee M, et al. (2005). Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood, 105, 526–532. doi:10.1182/blood-2004-03-1106
   PubMed Web of Science ®Google Scholar
• Loucks EB, Sullivan LM, D’Agostino Sr. RB, et al. (2006). Social networks and inflammatory markers in the Framingham heart study. J Biosoc Sci, 38, 835–842. doi:10.1017/s0021932005001203
   PubMed Web of Science ®Google Scholar
• Lowe GD, Rumley A, McMahon AD, et al. (2004). Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol, 24, 1529–1534. doi:10.1161/01.ATV.0000135995.39488.6c
   PubMed Web of Science ®Google Scholar
• McDermott MM, Liu K, Ferrucci L, et al. (2011). Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease. Am J Cardiol, 107, 1392–1398. doi:10.1016/j.amjcard.2011.01.007
   PubMed Web of Science ®Google Scholar
• McLoughlin RM, Hurst SM, Nowell MA, et al. (2004). Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol, 172, 5676–5683. doi:10.4049/jimmunol.172.9.5676
   PubMed Web of Science ®Google Scholar
• Misato H, Masahiko M. (2011). IL-6 and lipid metabolism. Inflamm Regen, 31, 79–80.
   Google Scholar
• Miwa K, Tanaka M, Okazaki S, et al. (2013). Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors. Arterioscler Thromb Vasc Biol, 33, 400–405. doi:10.1161/atvbaha.112.300350
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. (2016). Executive summary: heart disease and stroke statistics–2016 update: A report from the American Heart Association. Circulation, 133, 447–454. doi:10.1161/cir.0000000000000366
   PubMed Web of Science ®Google Scholar
• Pai JK, Pischon T, Ma J, et al. (2004). Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med, 351, 2599–2610. doi:10.1056/NEJMoa040967
   PubMed Web of Science ®Google Scholar
• Papanicolaou DA, Petrides JS, Tsigos C, et al. (1996a). Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol, 271, E601–5. doi:10.1152/ajpendo.1996.271.3.E601
   PubMed Web of Science ®Google Scholar
• Papanicolaou OA, Tsigos C, Torpy D, et al. (1996b). Recombinant interleukin-6 effects on pituitary secretion in humans. J Invest Med, 44, A266.
   Google Scholar
• Patterson CC, Smith AE, Yarnell JW, et al. (2010). The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the caerphilly study. Atherosclerosis, 209, 551–557. doi:10.1016/j.atherosclerosis.2009.09.030
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rossouw JE, et al. (2002). Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s health initiative observational study. Jama, 288, 980–987. doi:10.1001/jama.288.8.980
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. (2000a). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342, 836–843. doi:10.1056/nejm200003233421202
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. (2000b). Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 101, 1767–1772. doi:10.1161/01.CIR.101.15.1767
   PubMed Web of Science ®Google Scholar
• Stott DJ, Welsh P, Rumley A, et al. (2009). Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol, 38, 253–261. doi:10.1093/ije/dyn215
   PubMed Web of Science ®Google Scholar
• Straub RH, Hense HW, Andus T, et al. (2000). Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metabolism, 85, 1340–1344. doi:10.1210/jcem.85.3.6355
   PubMed Web of Science ®Google Scholar
• Torpy DJ, Papanicolaou DA, Lotsikas AJ, et al. (2000). Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum, 43, 872–880. doi:10.1002/1529-0131(200004)43:4<872::aid-anr19>3.0.co;2-t
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Murray GD, Lee AJ, et al. (2005). C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: edinburgh artery study. Circulation, 112, 976–983. doi:10.1161/circulationaha.104.513085
   PubMed Web of Science ®Google Scholar
• van der Meer IM, de Maat MP, Bots ML, et al. (2002). Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol, 22, 838–842. doi:10.1161/01.ATV.0000016249.96529.B8
   PubMed Web of Science ®Google Scholar
• Veldhuis GJ, Willemse PH, Sleijfer DT, et al. (1995). Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol, 13, 2585–2593. doi:10.1200/jco.1995.13.10.2585
   PubMed Web of Science ®Google Scholar
• Viola J, Soehnlein O. (2015). Atherosclerosis - A matter of unresolved inflammation. Semin Immunol, 27, 184–193. doi:10.1016/j.smim.2015.03.013
   PubMed Web of Science ®Google Scholar
• Welsh P, Woodward M, Rumley A, et al. (2010). Does interleukin-18 or tumour necrosis factor-alpha have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand. Cytokine, 50, 94–98. doi:10.1016/j.cyto.2009.12.014
   PubMed Web of Science ®Google Scholar
• Xiang S, Dong NG, Liu JP, et al. (2013). Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-gamma-induced vascular smooth muscle cells. J Huazhong Univ Sci Technolog Med Sci, 33, 615–622. doi:10.1007/s11596-013-1168-x
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang J, Xu Y, et al. (2015). Correlative association of interleukin-6 with intima media thickness: a meta-analysis. Int J Clin Exp Med, 8, 4731–4743.
   PubMed Web of Science ®Google Scholar